ArticleJournal for immunotherapy of cancer2025

PRMT5 deficiency in myeloid cells reprograms macrophages to enhance antitumor immunity and synergizes with anti-PD-L1 therapy.

Shiyu Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.